Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 18Colorectal Neoplasms 17Stomach Neoplasms 10Colonic Neoplasms 7Gastrointestinal Neoplasms 2Adenocarcinoma 2Turcot syndrome 1Recurrence 1Rcctal Cancer 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Gastric Cancer 1Locally Advanced Colorectal Cancer 1Intestinal Neoplasms 1HER2-positive Locally Advanced Resectable Gastric Cancer 1HER2-positive Colorectal Cancer 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Carcinoma 1Adebrelimab (SHR-1316) 1

Interventions

Oxaliplatin 3Ocoxin 3pembrolizumab 2Capecitabine 2penpulimab 1hetrombopag 1golotimod 1durvalumab 1camrelizumab 1aumolertinib 1alectinib 1XELOX 1Surgical Procedures, Operative 1Sunitinib 1Radiotherapy 1Paclitaxel 1Nivolumab 1Immunotherapy 1Imatinib Mesylate 1HhAntag691 1Gemcitabine 1Fluorouracil 1Cyclophosphamide 1Chemoradiotherapy 1Ascorbic Acid 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Digestive System Diseases × XELOX × Clear all
NCT05494060 2023-11-07

EXPLORING

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡